 |  |
Amgen Reports Positive Interim Results for IMDELLTRA in Small Cell Lung Cancer Study
IMDELLTRA demonstrated statistically significant and clinically meaningful improvement in overall survival compared to local standard-of-care chemotherapy.
IMDELLTRA | 14/04/2025 | By Abha
FDA Approves Amgen's IMDELLTRA for Advanced Small Cell Lung Cancer
The approval is based on the encouraging response rate and duration of response (DoR) observed in clinical studies, under the FDA's accelerated approval pathway.
IMDELLTRA | 17/05/2024 | By Abha | 212
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy